Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048875 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT05048875 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants.
The verdict
NCT05048875, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.
Interventions
- DRUG Cohort 1 - Group 1 JNJ High Dose
- DRUG Cohort 1 - Group 2 JNJ Medium Dose
- DRUG Cohort 1 - Group 2 JNJ Low Dose
- DRUG Cohort 1 - Group 1/2 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2024-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048875
The ClinicalTrials.gov registry entry for NCT05048875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cohort 1 - Group 1 JNJ High Dose is the first listed.
NCT05048875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05048875 about?
NCT05048875 is a clinical study titled "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge". The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult partic...
What is the current status of trial NCT05048875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-02-03. Estimated completion is 2024-09-10.
What interventions are being tested in trial NCT05048875?
The interventions under investigation include: Cohort 1 - Group 1 JNJ High Dose (DRUG), Cohort 1 - Group 2 JNJ Medium Dose (DRUG), Cohort 1 - Group 2 JNJ Low Dose (DRUG), Cohort 1 - Group 1/2 Placebo (DRUG).
Who is sponsoring clinical trial NCT05048875?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.